Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.79 USD
Change Today +0.01 / 0.13%
Volume 329.7K
SCLN On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/8/15 - $11.71
52 Week Low
10/8/14 - $6.59
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for oncology, infectious diseases, and cardiovascular disorders in the People’s Republic of China, the United States, and Hong Kong. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. The company also focuses on development ZADAXIN for the treatment of sepsis. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. In addition, it markets approximately seven partnered products in China, including Aggrastat, an interventional cardiology product. Further, the company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Holoxan, Mesna, Endoxan, Methotrexate, Estracyt, Farlutal, Neucardin, ProFlow, Angiomax, and Cleviprex. SciClone Pharmaceuticals, Inc. also has an agreement with MEDA Pharma GmbH & Co. KG for the development of Tramadol. The company was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/12/15
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $566.5K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $356.5K
Chief Executive Officer of China Operations
Total Annual Compensation: $543.4K
Vice President of Compliance and General Coun...
Total Annual Compensation: $448.3K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $301.1K
Compensation as of Fiscal Year 2014.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Full Year 2015

SciClone Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total net revenue of USD 37,946,000 compared to USD 32,513,000 a year ago. Loss from operations was USD 4,857,000 compared to income from operations of USD 9,640,000 a year ago. Loss before provision for income tax was USD 4,568,000 compared to income before benefit for income tax of USD 9,674,000 a year ago. Net loss USD 4,022,000 or USD 0.08 per diluted share compared to net income of USD 9,640,000 or USD 0.18 per diluted share a year ago. Non-GAAP net income USD 13,548,000 or USD 0.26 per diluted share compared to USD 10,533,000 or USD 0.20 per diluted share a year ago. For the six months, the company reported total net revenue of USD 71,514,000 compared to USD 59,078,000 a year ago. Income from operations was USD 4,626,000 compared to USD 14,301,000 a year ago. Income before provision for income tax was USD 4,964,000 compared to USD 14,206,000 a year ago. Net income USD 4,940,000 or USD 0.09 per diluted share compared to USD 13,774,000 or USD 0.26 per diluted share a year ago. Non-GAAP net income USD 23,316,000 or USD 0.44 per diluted share compared to USD 15,549,000 or USD 0.29 per diluted share a year ago. The company currently anticipates the price reduction will have limited impact on its overall revenue, and it is maintaining its full-year revenue guidance of between USD 153 million and USD 158 million and non-GAAP EPS guidance of between USD 0.73 and USD 0.77, as previously reported.

SciClone Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 10, 2015

SciClone Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 10, 2015

SciClone Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015

SciClone Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 10, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $7.79 USD +0.01

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $41.03 USD -0.18
Lannett Co Inc $49.87 USD -0.17
Momenta Pharmaceuticals Inc $20.37 USD +0.15
Pernix Therapeutics Holdings Inc $4.70 USD +0.10
Sagent Pharmaceuticals Inc $20.04 USD +0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation SCLN Industry Range
Price/Earnings 24.9x
Price/Sales 2.6x
Price/Book 2.4x
Price/Cash Flow 23.9x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at